Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
While numerous studies have evaluated humoral responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, data on the cellular responses to these vaccines remain sparse. We evaluated T cell responses to ChAdOx1-nCoV-19 and BNT162b2 vaccinations using an interferon gamma (IFN-γ) release assay (IGRA). ChAdOx1-nCoV-19- and BNT162b2-vaccinated participants initially showed stronger T cell responses than unvaccinated controls. The T cell response decreased over time and increased substantially after the administration of a BNT162b2 booster dose. Changes in the T cell response were less significant than those in the anti-receptor-binding domain IgG antibody titer. The study results can serve as baseline data for T cell responses after SARS-CoV-2 vaccination and suggest that the IGRA can be useful in monitoring immunogenicity.
Abstract
While numerous studies have evaluated humoral responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, data on the cellular responses to these vaccines remain sparse. We evaluated T cell responses to ChAdOx1-nCoV-19 and BNT162b2 vaccinations using an interferon gamma (IFN-γ) release assay (IGRA). ChAdOx1-nCoV-19- and BNT162b2-vaccinated participants initially showed stronger T cell responses than unvaccinated controls. The T cell response decreased over time and increased substantially after the administration of a BNT162b2 booster dose. Changes in the T cell response were less significant than those in the anti-receptor-binding domain IgG antibody titer. The study results can serve as baseline data for T cell responses after SARS-CoV-2 vaccination and suggest that the IGRA can be useful in monitoring immunogenicity.
참고문헌 (19)
- Wu F, "A new coronavirus associated with human respiratory disease in China", Nature, 579, pp.265~269 (2020)
- Cham J, "6 month serologic response to the Pfizer-BioNTech COVID-19 vaccine among healthcare workers", PLoS One, 17, pp.e0266781~ (2022)
- Robertson LJ, "IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination : a Northern Ireland observational study", Vaccine, 40, pp.2535~2539 (2022)
- Kim Jung-Ah, "Immunogenicity of Third-dose BNT162b2 mRNA Vaccine Following Two Doses of ChAdOx1 in Health Care Workers: A Prospective Longitudinal Study", Annals of Laboratory Medicine, 42(6), pp.688~692 (2022), 대한진단검사의학회[DOI]
- Cameroni E, "Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift", Nature, 602, pp.664~670 (2022)
- Zhuang Z, "Mapping and role of T cell response in SARS-CoV-2-infected mice", J Exp Med, 218, pp.e20202187~ (2021)
- McMahan K, "Correlates of protection against SARS-CoV-2 in rhesus macaques", Nature, 590, pp.630~634 (2021)
- Woldemeskel BA, "SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63", J Clin Invest, 131, pp.e149335~ (2021)
- Geers D, "SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees", Sci Immunol, 6, pp.eabj1750~ (2021)
- Jung MK, "BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality", Nat Microbiol, 7, pp.909~917 (2022)
- Mukaka MM, "Statistics corner : a guide to appropriate use of correlation coefficient in medical research", Malawi Med J, 24, pp.69~71 (2012)
- Busà R, "Specific anti-SARS-CoV-2 humoral and cellular immune responses after booster dose of BNT162b2 Pfizer-BioNTech mRNA-based vaccine : integrated study of adaptive immune system components", Front Immunol, 13, pp.856657~ (2022)
- Groß R, "Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants", EBioMedicine, 75, pp.103761~ (2022)
- Shaw RH, "Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial", Lancet Respir Med (2022)
- Qui M, "Favorable vaccine-induced SARS-CoV-2-specific T cell response profile in patients undergoing immune-modifying therapies", J Clin Invest, 132, pp.e159500~ (2022)
- Yao L, "Persistence of antibody and cellular immune responses in coronavirus disease 2019 patients over nine months after infection", J Infect Dis, 224, pp.586~594 (2021)
- Le Bert N, "SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls", Nature, 584, pp.457~462 (2020)
- Chen J, "Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance", J Chem Inf Model, 62, pp.412~422 (2022)
- Tarke A, "SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron", Cell, 185, pp.847~859 (2022)